Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420327 · ClinicalTrials.gov registry record · NA
Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02420327 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 43 participants.
The verdict
NCT02420327, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4 mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24 mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the presence of this low dose of galantamine.
Interventions
- DRUG Placebo patch & placebo capsule
- DRUG Placebo patch & galantamine capsule
- DRUG Nicotine patch & placebo capsule
- DRUG Nicotine patch and galantamine capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02420327
The ClinicalTrials.gov registry entry for NCT02420327 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo patch & placebo capsule is the first listed.
NCT02420327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02420327 about?
NCT02420327 is a clinical study titled "Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine". The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicot...
What is the current status of trial NCT02420327?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2014-09. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02420327?
The interventions under investigation include: Placebo patch & placebo capsule (DRUG), Placebo patch & galantamine capsule (DRUG), Nicotine patch & placebo capsule (DRUG), Nicotine patch and galantamine capsule (DRUG).
Who is sponsoring clinical trial NCT02420327?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.